Torrent Pharmaceuticals Limited has informed the Exchange regarding 'Dividend Payment Date'.
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts more than Nifty 100 and 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Torrent Pharmaceuticals' board approved an interim dividend of ₹29 per share (580% on face value of ₹5), with payment expected on or around March 6, 2026. The company also reported Q3 FY26 consolidated revenue of ₹3,303 crore, up 18% year-on-year, with operating EBITDA at ₹1,088 crore (33% margin) and net profit of ₹635 crore, up 26% year-on-year. For the first nine months of FY26, revenue grew 14% to ₹9,783 crore and net profit rose 26% to ₹1,774 crore. The company also completed its acquisition of a 48.8% controlling stake in JB Chemicals & Pharmaceuticals, effective January 21, 2026, with a proposed merger swap ratio of 51 Torrent shares for every 100 JB Pharma shares. India revenues grew 14% to ₹1,798 crore, while Brazil and the US businesses also posted strong double-digit growth.
Positive for shareholders — strong Q3 profit growth of 26% supports a healthy interim dividend payout, and the completed JB Pharma acquisition makes Torrent the 5th largest pharma company in India, likely boosting long-term scale and earnings. The stock may see near-term support from the dividend, while investor focus will shift to merger approval timelines and integration.